Biosimilar Opportunity Scanner
470
Biologics tracked
0
A+ targets
8
A-grade targets
35
Window open / imminent
Free tier: first 25 rows · Upgrade to Pro for full 470-row export.
| Grade | Score | Reference biologic | Originator | Revenue | BPCIA window | Expiry | Active patents | Avg vuln |
|---|---|---|---|---|---|---|---|---|
| A | 70 |
Keytruda
pembrolizumab
|
Merck & Co. | $29.5B | imminent Window opens in 0.3 yrs |
2026-09-04 | 0 | — |
| A | 65 |
Vegf Trap
AFLIBERCEPT
|
Regeneron | $9.8B | imminent Window open now (expired 2.5 yrs ago) |
2023-11-18 | 0 | — |
| A | 65 |
Entyvio
vedolizumab
|
Takeda | $7.3B | imminent Window opens in 0.0 yrs |
2026-05-20 | 0 | — |
| A | 65 |
Trulicity
DULAGLUTIDE
|
Eli Lilly | $7.2B | imminent Window opens in 0.3 yrs |
2026-09-18 | 0 | — |
| A | 65 |
Opdivo
nivolumab
|
Bristol-Myers Squibb | $9.2B | imminent Window opens in 0.6 yrs |
2026-12-22 | 0 | — |
| A | 65 |
Darzalex
daratumumab
|
Johnson & Johnson | $11.8B | open 1.5 yrs to entry (dev window) |
2027-11-16 | 0 | — |
| A | 65 |
Dupixent
DUPILUMAB
|
Regeneron | $14.6B | open 2.9 yrs to entry (dev window) |
2029-03-28 | 0 | — |
| A | 60 |
Ocrevus
OCRELIZUMAB
|
Roche | $6.5B | open 2.9 yrs to entry (dev window) |
2029-03-28 | 0 | — |
| B | 58 |
Cosentyx
secukinumab
|
Novartis | $3.9B | imminent Window opens in 0.7 yrs |
2027-01-21 | 0 | — |
| B | 58 |
Lantus
INSULIN GLARGINE
|
Sanofi | $4.8B | imminent Window opens in 0.8 yrs |
2027-02-25 | 0 | — |
| B | 53 |
Humalog
INSULIN LISPRO
|
Eli Lilly | $2.2B | open 1.0 yrs to entry (dev window) |
2027-05-26 | 0 | — |
| B | 53 |
Tresiba
INSULIN DEGLUDEC
|
Novo Nordisk | $4.5B | open 1.4 yrs to entry (dev window) |
2027-09-25 | 0 | — |
| B | 53 |
Lantus
INSULIN GLARGINE
|
Sanofi | $4.8B | open 1.6 yrs to entry (dev window) |
2027-12-16 | 0 | — |
| B | 53 |
Taltz
ixekizumab
|
Eli Lilly | $2.7B | open 1.8 yrs to entry (dev window) |
2028-03-22 | 0 | — |
| B | 53 |
Tecentriq
atezolizumab
|
Roche | $3.7B | open 2.0 yrs to entry (dev window) |
2028-05-18 | 0 | — |
| B | 53 |
Imfinzi
durvalumab
|
AstraZeneca | $4.9B | open 3.0 yrs to entry (dev window) |
2029-05-01 | 0 | — |
| B | 52 |
Blincyto
blinatumomab
|
Amgen | $1.0B | imminent Window opens in 0.5 yrs |
2026-12-03 | 0 | — |
| B | 50 |
Ultomiris
RAVULIZUMAB
|
AstraZeneca | $5.1B | open 4.6 yrs to entry |
2030-12-21 | 0 | — |
| B | 50 |
Skyrizi
RISANKIZUMAB
|
AbbVie | $8.6B | open 4.9 yrs to entry |
2031-04-23 | 0 | — |
| B | 47 |
Nucala
MEPOLIZUMAB
|
GSK | $1.6B | open 1.5 yrs to entry (dev window) |
2027-11-04 | 0 | — |
| B | 46 |
Adcetris
brentuximab-vedotin
|
Pfizer | $900M | imminent Window open now (expired 2.7 yrs ago) |
2023-08-19 | 0 | — |
| B | 46 |
Kadcyla
trastuzumab-emtansine
|
Roche | $900M | imminent Window open now (expired 1.2 yrs ago) |
2025-02-22 | 0 | — |
| B | 46 |
Rhgalns
ELOSULFASE ALFA
|
BioMarin | $500M | imminent Window open now (expired 0.3 yrs ago) |
2026-02-14 | 0 | — |
| B | 46 |
Cyramza
RAMUCIRUMAB
|
Eli Lilly | $900M | imminent Window open now (expired 0.1 yrs ago) |
2026-04-21 | 0 | — |
| B | 46 |
Plegridy
PEGINTERFERON BETA-1A
|
Biogen Idec Inc | $800M | imminent Window opens in 0.2 yrs |
2026-08-15 | 0 | — |
| B | 45 |
Botox
ONABOTULINUMTOXINA
|
Allergan | $5.3B | saturated Expired 22 yrs ago |
2003-12-09 | 0 | — |
| B | 45 |
Stelara
ustekinumab
|
Johnson & Johnson | $9.5B | saturated Expired 5 yrs ago |
2021-09-25 | 0 | — |
| B | 45 |
Prolia
DENOSUMAB
|
Amgen | $6.1B | saturated Expired 4 yrs ago |
2022-06-01 | 0 | — |
| B | 45 |
Prolia
DENOSUMAB
|
Amgen | $6.1B | saturated Expired 3 yrs ago |
2023-03-25 | 0 | — |
| B | 45 |
Abrilada
Adalimumab-Afzb
|
AbbVie | $10.2B | distant 5 yrs to entry (early) |
2031-11-15 | 0 | — |
| C | 43 |
Tremfya
GUSELKUMAB
|
Johnson & Johnson | $3.6B | open 3.2 yrs to entry |
2029-07-13 | 0 | — |
| C | 43 |
Hemlibra
EMICIZUMAB
|
Roche | $4.8B | open 3.5 yrs to entry |
2029-11-16 | 0 | — |
| C | 43 |
Humalog
INSULIN LISPRO
|
Eli Lilly | $2.2B | open 3.6 yrs to entry |
2029-12-11 | 0 | — |
| C | 41 |
Praluent
ALIROCUMAB
|
Sanofi | $857M | open 1.2 yrs to entry (dev window) |
2027-07-24 | 0 | — |
| C | 40 |
Skyrizi
RISANKIZUMAB
|
AbbVie | $8.6B | distant 6 yrs to entry (early) |
2032-03-02 | 0 | — |
| C | 40 |
Vabysmo
FARICIMAB
|
Roche | $5.5B | distant 8 yrs to entry (early) |
2034-01-28 | 0 | — |
| C | 40 |
Skyrizi
RISANKIZUMAB
|
AbbVie | $8.6B | distant 8 yrs to entry (early) |
2034-06-16 | 0 | — |
| C | 40 |
Vegf Trap
AFLIBERCEPT
|
Regeneron | $9.8B | distant 9 yrs to entry (early) |
2035-08-18 | 0 | — |
| C | 40 |
Entyvio
vedolizumab
|
Takeda | $7.3B | distant 9 yrs to entry (early) |
2035-09-27 | 0 | — |
| C | 40 |
Prolia
DENOSUMAB
|
Amgen | $6.1B | distant 10 yrs to entry (early) |
2036-03-05 | 0 | — |
| C | 40 |
Stelara
ustekinumab
|
Johnson & Johnson | $9.5B | distant 11 yrs to entry (early) |
2036-11-29 | 0 | — |
| C | 40 |
Prolia
DENOSUMAB
|
Amgen | $6.1B | distant 11 yrs to entry (early) |
2037-03-25 | 0 | — |
| C | 40 |
Prolia
DENOSUMAB
|
Amgen | $6.1B | distant 11 yrs to entry (early) |
2037-08-29 | 0 | — |
| C | 40 |
Prolia
DENOSUMAB
|
Amgen | $6.1B | distant 11 yrs to entry (early) |
2037-10-29 | 0 | — |
| C | 38 |
Humalog
INSULIN LISPRO
|
Eli Lilly | $2.2B | saturated Expired 18 yrs ago |
2008-06-14 | 0 | — |
| C | 38 |
Herceptin
trastuzumab
|
Roche | $2.9B | saturated Expired 16 yrs ago |
2010-09-25 | 0 | — |
| C | 38 |
Enbrel
etanercept
|
Immunex | $3.1B | saturated Expired 16 yrs ago |
2010-11-02 | 0 | — |
| C | 38 |
Humalog
INSULIN LISPRO
|
Eli Lilly | $2.2B | saturated Expired 14 yrs ago |
2011-12-22 | 0 | — |
| C | 38 |
Humalog
INSULIN LISPRO
|
Eli Lilly | $2.2B | saturated Expired 14 yrs ago |
2011-12-22 | 0 | — |
| C | 38 |
Lantus
INSULIN GLARGINE
|
Sanofi | $4.8B | saturated Expired 14 yrs ago |
2012-04-20 | 0 | — |
| C | 38 |
Novolog
INSULIN ASPART
|
Novo Nordisk | $2.8B | saturated Expired 14 yrs ago |
2012-06-07 | 0 | — |
| C | 38 |
Herceptin
trastuzumab
|
Roche | $2.9B | saturated Expired 13 yrs ago |
2013-05-07 | 0 | — |
| C | 38 |
Novolog
INSULIN ASPART
|
Novo Nordisk | $2.8B | saturated Expired 13 yrs ago |
2013-11-01 | 0 | — |
| C | 38 |
Xolair
omalizumab
|
Roche | $3.2B | saturated Expired 11 yrs ago |
2015-06-20 | 0 | — |
| C | 38 |
Avastin
bevacizumab
|
Roche | $2.1B | saturated Expired 10 yrs ago |
2016-02-26 | 0 | — |
| C | 38 |
Orencia
abatacept
|
Bristol-Myers Squibb | $3.7B | saturated Expired 8 yrs ago |
2017-12-23 | 0 | — |
| C | 37 |
Lymphostat B
BELIMUMAB
|
Human Genome Sciences Inc. | $1.1B | open 3.2 yrs to entry |
2029-07-20 | 0 | — |
| C | 37 |
Fasenra
BENRALIZUMAB
|
AstraZeneca | $1.8B | open 3.5 yrs to entry |
2029-11-14 | 0 | — |
| C | 37 |
Neupogen
Filgrastim-Aafi
|
Amgen | $1.4B | open 4.2 yrs to entry |
2030-07-20 | 0 | — |
| C | 37 |
Libtayo
CEMIPLIMAB
|
Regeneron Pharmaceuticals | $1.5B | open 4.4 yrs to entry |
2030-09-28 | 0 | — |
| C | 35 |
Tivdak
tisotumab-vedotin
|
SEAGEN | $147M | open 2.4 yrs to entry (dev window) |
2028-09-23 | 0 | — |
| C | 35 |
Bavencio
avelumab
|
Merck KGaA | $400M | open 2.8 yrs to entry (dev window) |
2029-03-23 | 0 | — |
| C | 33 |
Enhertu
trastuzumab-deruxtecan
|
Daiichi Sankyo | $2.9B | distant 6 yrs to entry (early) |
2031-12-20 | 0 | — |
| C | 33 |
Tepezza
TEPROTUMUMAB
|
Horizon Therapeutics Ireland | $2.0B | distant 6 yrs to entry (early) |
2032-01-21 | 0 | — |
| C | 33 |
Repatha
EVOLOCUMAB
|
Repatha | $2.1B | distant 7 yrs to entry (early) |
2033-02-26 | 0 | — |
| C | 33 |
Vyvgart
EFGARTIGIMOD ALFA
|
Argenx Bv | $2.5B | distant 8 yrs to entry (early) |
2033-12-17 | 0 | — |
| C | 33 |
Cosentyx
secukinumab
|
Novartis | $3.9B | distant 9 yrs to entry (early) |
2035-10-06 | 0 | — |
| C | 33 |
Avastin
bevacizumab
|
Roche | $2.1B | distant 10 yrs to entry (early) |
2035-12-06 | 0 | — |
| C | 32 |
Neupogen
Filgrastim-Aafi
|
Amgen | $1.4B | saturated Expired 23 yrs ago |
2003-02-20 | 0 | — |
| C | 32 |
Neulasta
Pegfilgrastim-Apgf
|
Amgen | $1.2B | saturated Expired 12 yrs ago |
2014-01-31 | 0 | — |
| C | 32 |
Fabrazyme
AGALSIDASE BETA
|
Sanofi | $1.0B | saturated Expired 11 yrs ago |
2015-04-24 | 0 | — |
| C | 32 |
Tysabri
NATALIZUMAB
|
Biogen Idec | $1.6B | saturated Expired 9 yrs ago |
2016-11-23 | 0 | — |
| C | 32 |
Cimzia
CERTOLIZUMAB PEGOL
|
UCB | $1.6B | saturated Expired 6 yrs ago |
2020-04-22 | 0 | — |
| C | 32 |
Nplate
ROMIPLOSTIM
|
Amgen | $1.5B | saturated Expired 6 yrs ago |
2020-08-22 | 0 | — |
| C | 32 |
Ilaris
CANAKINUMAB
|
Novartis Pharms | $1.4B | saturated Expired 5 yrs ago |
2021-06-17 | 0 | — |
| C | 32 |
Rhgaa
ALGLUCOSIDASE ALFA
|
Sanofi | $1.1B | saturated Expired 4 yrs ago |
2022-05-24 | 0 | — |
| C | 32 |
Lymphostat B
BELIMUMAB
|
Human Genome Sciences Inc. | $1.1B | saturated Expired 3 yrs ago |
2023-03-09 | 0 | — |
| C | 31 |
Aimovig
ERENUMAB
|
Amgen | $500M | open 4.0 yrs to entry |
2030-05-17 | 0 | — |
| C | 31 |
Ajovy
FREMANEZUMAB
|
Teva | $600M | open 4.3 yrs to entry |
2030-09-14 | 0 | — |
| C | 31 |
Emgality
GALCANEZUMAB
|
Eli Lilly | $500M | open 4.4 yrs to entry |
2030-09-27 | 0 | — |
| C | 30 |
Nulojix
BELATACEPT
|
Bristol-Myers Squibb | — | imminent Window open now (expired 2.9 yrs ago) |
2023-06-15 | 0 | — |
| C | 30 | (unknown) | SEATTLE GENETICS | — | imminent Window open now (expired 2.7 yrs ago) |
2023-08-19 | 0 | — |
| C | 30 |
Voraxaze
GLUCARPIDASE
|
Btg International Inc | — | imminent Window open now (expired 2.3 yrs ago) |
2024-01-17 | 0 | — |
| C | 30 |
VIOKACE
PANCRELIPASE
|
VIOKACE | — | imminent Window open now (expired 2.2 yrs ago) |
2024-03-01 | 0 | — |
| C | 30 |
Elelyso
Taliglucerase Alfa
|
Pfizer Inc. | — | imminent Window open now (expired 2.0 yrs ago) |
2024-05-01 | 0 | — |
| C | 30 |
PERTZYE
PANCRELIPASE
|
DIGESTIVE CARE INC | — | imminent Window open now (expired 2.0 yrs ago) |
2024-05-17 | 0 | — |
| C | 30 |
Perjeta
pertuzumab
|
Roche | — | imminent Window open now (expired 1.9 yrs ago) |
2024-06-08 | 0 | — |
| C | 30 |
ZALTRAP
Ziv aflibercept
|
Marashi Eye Clinic | — | imminent Window open now (expired 1.8 yrs ago) |
2024-08-03 | 0 | — |
| C | 30 |
GRANIX
tbo-filgrastim
|
Teva Branded Pharmaceutical Products R&D, Inc. | — | imminent Window open now (expired 1.7 yrs ago) |
2024-08-29 | 0 | — |
| C | 30 | (unknown) | THROMBOGENICS, INC | — | imminent Window open now (expired 1.6 yrs ago) |
2024-10-17 | 0 | — |
| C | 30 | RAXIBACUMAB | HUMAN GENOME SCIENCES INC. | — | imminent Window open now (expired 1.4 yrs ago) |
2024-12-14 | 0 | — |
| C | 30 |
Simponi
GOLIMUMAB
|
Centocor Ortho Biotech Inc | — | imminent Window open now (expired 0.8 yrs ago) |
2025-07-18 | 0 | — |
| C | 30 |
Roactemra
tocilizumab
|
Roche | — | imminent Window open now (expired 0.6 yrs ago) |
2025-10-21 | 0 | — |
| C | 30 |
GAZYVA
OBINUTUZUMAB
|
GENENTECH | — | imminent Window open now (expired 0.5 yrs ago) |
2025-11-01 | 0 | — |
| C | 30 |
Myalept
METRELEPTIN
|
Amylin Pharms Llc | — | imminent Window open now (expired 0.2 yrs ago) |
2026-02-24 | 0 | — |
| C | 30 | (unknown) | GLAXOSMITHKLINE LLC | — | imminent Window open now (expired 0.1 yrs ago) |
2026-04-15 | 0 | — |
| C | 30 | SYLVANT | RECORDATI RARE DISEASES, INC. | — | imminent Window open now (expired 0.1 yrs ago) |
2026-04-23 | 0 | — |
| C | 30 |
AFREZZA
INSULIN HUMAN
|
MANNKIND | — | imminent Window opens in 0.1 yrs |
2026-06-27 | 0 | — |
| C | 30 | (unknown) | NPS PHARMS INC | — | imminent Window opens in 0.7 yrs |
2027-01-23 | 0 | — |
| C | 30 | (unknown) | BRISTOL MYERS SQUIBB | — | imminent Window opens in 0.8 yrs |
2027-03-04 | 0 | — |
| C | 30 |
ZARXIO
Filgrastim-sndz
|
M.D. Anderson Cancer Center | — | imminent Window opens in 0.8 yrs |
2027-03-06 | 0 | — |
| C | 30 |
Ch14.18
DINUTUXIMAB
|
United Therap | — | imminent Window opens in 0.8 yrs |
2027-03-10 | 0 | — |
| C | 27 |
Nucala
MEPOLIZUMAB
|
GSK | $1.6B | distant 5 yrs to entry (early) |
2031-06-06 | 0 | — |
| C | 27 |
Polivy
POLATUZUMAB VEDOTIN
|
Roche | $1.6B | distant 5 yrs to entry (early) |
2031-06-10 | 0 | — |
| C | 27 |
Neulasta
Pegfilgrastim-Apgf
|
Amgen | $1.2B | distant 6 yrs to entry (early) |
2032-06-10 | 0 | — |
| C | 26 |
Cerezyme
IMIGLUCERASE
|
Sanofi | $800M | saturated Expired 20 yrs ago |
2006-05-23 | 0 | — |
| C | 26 |
Avonex
INTERFERON BETA-1A
|
Biogen | $800M | saturated Expired 18 yrs ago |
2008-05-17 | 0 | — |
| C | 26 |
Avonex
INTERFERON BETA-1A
|
Biogen | $800M | saturated Expired 12 yrs ago |
2014-03-07 | 0 | — |
| C | 26 |
Wydase
HYALURONIDASE
|
Baxter | $900M | saturated Expired 10 yrs ago |
2016-10-26 | 0 | — |
| C | 26 |
Wydase
HYALURONIDASE
|
Baxter | $900M | saturated Expired 8 yrs ago |
2017-12-02 | 0 | — |
| C | 25 | (unknown) | NOVO | — | open 1.4 yrs to entry (dev window) |
2027-09-25 | 0 | — |
| C | 25 |
Praxbind
IDARUCIZUMAB
|
Boehringer Ingelheim | — | open 1.4 yrs to entry (dev window) |
2027-10-16 | 0 | — |
| C | 25 |
Strensiq
ASFOTASE ALFA
|
AstraZeneca | — | open 1.4 yrs to entry (dev window) |
2027-10-23 | 0 | — |
| C | 25 |
Portrazza
NECITUMUMAB
|
Eli Lilly Co | — | open 1.5 yrs to entry (dev window) |
2027-11-24 | 0 | — |
| C | 25 |
Huluc63
elotuzumab
|
Bristol-Myers Squibb | — | open 1.5 yrs to entry (dev window) |
2027-11-30 | 0 | — |
| C | 25 | KANUMA | ALEXION PHARM | — | open 1.6 yrs to entry (dev window) |
2027-12-08 | 0 | — |
| C | 25 |
Anthim
OBILTOXAXIMAB
|
Elusys Therapeutics Inc | — | open 1.8 yrs to entry (dev window) |
2028-03-18 | 0 | — |
| C | 25 |
Cinqair
RESLIZUMAB
|
Teva Respiratory Llc | — | open 1.8 yrs to entry (dev window) |
2028-03-23 | 0 | — |
| C | 25 |
INFLECTRA
Infliximab-Dyyb
|
Asan Medical Center | — | open 1.9 yrs to entry (dev window) |
2028-04-05 | 0 | — |
| C | 25 | (unknown) | BIOGEN | — | open 2.0 yrs to entry (dev window) |
2028-05-27 | 0 | — |
| C | 25 | (unknown) | SANOFI-AVENTIS US | — | open 2.2 yrs to entry (dev window) |
2028-07-27 | 0 | — |
| C | 25 | (unknown) | SANDOZ | — | open 2.3 yrs to entry (dev window) |
2028-08-30 | 0 | — |
| C | 25 | AMJEVITA | AMGEN INC | — | open 2.4 yrs to entry (dev window) |
2028-09-23 | 0 | — |
| C | 25 | (unknown) | GENENTECH INC | — | open 2.4 yrs to entry (dev window) |
2028-10-18 | 0 | — |
| C | 25 | (unknown) | ELI LILLY AND CO | — | open 2.4 yrs to entry (dev window) |
2028-10-19 | 0 | — |
| C | 25 |
Zinplava
BEZLOTOXUMAB
|
Merck & Co. | — | open 2.4 yrs to entry (dev window) |
2028-10-21 | 0 | — |
| C | 25 | SOLIQUA 100/33 | SANOFI-AVENTIS US | — | open 2.5 yrs to entry (dev window) |
2028-11-21 | 0 | — |
| C | 25 | XULTOPHY 100/3.6 | NOVO | — | open 2.5 yrs to entry (dev window) |
2028-11-21 | 0 | — |
| C | 25 |
Kyntheum
BRODALUMAB
|
Valeant Luxembourg | — | open 2.7 yrs to entry (dev window) |
2029-02-15 | 0 | — |
| C | 25 |
Remicade
infliximab
|
Johnson & Johnson | — | open 2.9 yrs to entry (dev window) |
2029-04-21 | 0 | — |
| C | 25 |
Rhttp1
CERLIPONASE ALFA
|
BioMarin | — | open 2.9 yrs to entry (dev window) |
2029-04-27 | 0 | — |
| C | 25 | (unknown) | EMD SERONO INC | — | open 3.0 yrs to entry (dev window) |
2029-05-09 | 0 | — |
| C | 25 |
BESPONSA
INOTUZUMAB OZOGAMICIN
|
WYETH PHARMS INC | $200M | open 3.2 yrs to entry |
2029-08-17 | 0 | — |
| C | 25 |
Mylotarg
GEMTUZUMAB
|
Wyeth Pharms Inc | $100M | open 3.3 yrs to entry |
2029-09-01 | 0 | — |
| C | 25 |
Epogen
Epoetin Alfa-Epbx
|
Amgen | $400M | open 4.0 yrs to entry |
2030-05-15 | 0 | — |
| C | 25 |
Poteligeo
MOGAMULIZUMAB
|
Kyowa Kirin | $300M | open 4.2 yrs to entry |
2030-08-08 | 0 | — |
| C | 21 |
Sunpg 1622
TILDRAKIZUMAB
|
Sun Pharma Global | $500M | distant 5 yrs to entry (early) |
2031-06-13 | 0 | — |
| C | 21 |
Trodelvy
sacituzumab-govitecan
|
Immunomedics Inc | $800M | distant 6 yrs to entry (early) |
2032-04-22 | 0 | — |
| C | 21 |
Saphnelo
ANIFROLUMAB
|
AstraZeneca | $700M | distant 7 yrs to entry (early) |
2033-07-30 | 0 | — |
| C | 21 |
Tezspire
AMG 157
|
AstraZeneca | $800M | distant 8 yrs to entry (early) |
2033-12-17 | 0 | — |
| C | 21 |
Saphnelo
ANIFROLUMAB
|
AstraZeneca | $700M | distant 12 yrs to entry (early) |
2038-04-24 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 28 yrs ago |
1998-10-16 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 19 yrs ago |
2007-05-25 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 19 yrs ago |
2007-08-24 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 18 yrs ago |
2007-12-29 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 18 yrs ago |
2008-08-23 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 14 yrs ago |
2012-06-20 | 0 | — |
| C | 20 |
Aranesp
DARBEPOETIN ALFA
|
Amgen | $400M | saturated Expired 13 yrs ago |
2013-09-17 | 0 | — |
| C | 20 |
Aldurazyme
LARONIDASE
|
BioMarin | $300M | saturated Expired 11 yrs ago |
2015-04-30 | 0 | — |
| C | 20 |
Aryplase
GALSULFASE
|
BioMarin | $400M | saturated Expired 9 yrs ago |
2017-05-31 | 0 | — |
| C | 20 |
Omnitrope
Somatropin
|
Serono | $446M | saturated Expired 8 yrs ago |
2018-05-30 | 0 | — |
| C | 15 |
KEVZARA
SARILUMAB
|
SANOFI SYNTHELABO | — | open 3.0 yrs to entry |
2029-05-22 | 0 | — |
| C | 15 | RITUXAN HYCELA | GENENTECH INC | — | open 3.1 yrs to entry |
2029-06-22 | 0 | — |
| C | 15 |
CYLTEZO
ADALIMUMAB-ADBM
|
BOEHRINGER INGELHEIM | — | open 3.3 yrs to entry |
2029-08-25 | 0 | — |
| C | 15 |
MVASI
Bevacizumab-awwb
|
Amgen | — | open 3.3 yrs to entry |
2029-09-14 | 0 | — |
| C | 15 | FIASP | NOVO | — | open 3.4 yrs to entry |
2029-09-29 | 0 | — |
| C | 15 |
Mepsevii
VESTRONIDASE ALFA
|
Ultragenyx Pharm Inc | — | open 3.5 yrs to entry |
2029-11-15 | 0 | — |
| C | 15 |
OGIVRI
TRASTUZUMAB-DKST
|
MYLAN GMBH | — | open 3.5 yrs to entry |
2029-12-01 | 0 | — |
| C | 15 | (unknown) | PFIZER INC | — | open 3.6 yrs to entry |
2029-12-13 | 0 | — |
| C | 15 |
Trogarzo
IBALIZUMAB
|
Taimed Biologics Usa | — | open 3.8 yrs to entry |
2030-03-06 | 0 | — |
| C | 15 |
ILUMYA
TILDRAKIZUMAB-ASMN
|
SUN PHARMA GLOBAL | — | open 3.8 yrs to entry |
2030-03-20 | 0 | — |
| C | 15 |
CRYSVITA
BUROSUMAB-TWZA
|
KYOWA KIRIN | — | open 3.9 yrs to entry |
2030-04-17 | 0 | — |
| C | 15 |
PALYNZIQ
Pegvaliase-Pqpz
|
University of Missouri-Columbia | — | open 4.0 yrs to entry |
2030-05-24 | 0 | — |
| C | 15 |
FULPHILA
PEGFILGRASTIM-JMDB
|
MYLAN GMBH | — | open 4.0 yrs to entry |
2030-06-04 | 0 | — |
| C | 15 |
Oxervate
CENEGERMIN
|
Dompe farmaceutici s.p.a. | — | open 4.3 yrs to entry |
2030-08-22 | 0 | — |
| C | 15 |
TAKHZYRO
LANADELUMAB-FLYO
|
DYAX CORP. | — | open 4.3 yrs to entry |
2030-08-23 | 0 | — |
| C | 15 | (unknown) | INNATE PHARMA | — | open 4.3 yrs to entry |
2030-09-13 | 0 | — |
| C | 15 |
Revcovi
ELAPEGADEMASE
|
Leadiant Biosci Inc | — | open 4.4 yrs to entry |
2030-10-05 | 0 | — |
| C | 15 |
HYRIMOZ
ADALIMUMAB-ADAZ
|
SANDOZ INC | — | open 4.5 yrs to entry |
2030-10-30 | 0 | — |
| C | 15 |
UDENYCA
Pegfilgrastim-Cbqv
|
Coherus Oncology, Inc. | — | open 4.5 yrs to entry |
2030-11-02 | 0 | — |
| C | 15 |
GAMIFANT
Emapalumab-Lzsg
|
Swedish Orphan Biovitrum | — | open 4.5 yrs to entry |
2030-11-20 | 0 | — |
| C | 15 |
TRUXIMA
RITUXIMAB-ABBS
|
CELLTRION INC | — | open 4.5 yrs to entry |
2030-11-28 | 0 | — |
| C | 15 |
HERZUMA
TRASTUZUMAB-PKRB
|
CELLTRION INC | — | open 4.6 yrs to entry |
2030-12-14 | 0 | — |
| C | 15 |
Asparlas
calaspargase
|
Pfizer | — | open 4.6 yrs to entry |
2030-12-20 | 0 | — |
| C | 15 |
Molecule 129
TAGRAXOFUSP
|
Stemline Therapeeutics Inc | — | open 4.6 yrs to entry |
2030-12-21 | 0 | — |
| C | 15 |
ONTRUZANT
TRASTUZUMAB-DTTB
|
SAMSUNG BIOEPIS CO LTD | — | open 4.7 yrs to entry |
2031-01-18 | 0 | — |
| C | 15 | JEUVEAU | EVOLUS INC | — | open 4.7 yrs to entry |
2031-02-01 | 0 | — |
| C | 15 |
CABLIVI
CAPLACIZUMAB-YHDP
|
ABLYNX NV | — | open 4.7 yrs to entry |
2031-02-06 | 0 | — |
| C | 15 |
HERCEPTIN HYLECTA
Trastuzumab and Hyaluronidase-oysk
|
Adrienne G. Waks | — | open 4.8 yrs to entry |
2031-02-28 | 0 | — |
| C | 15 |
Herceptin
Trastuzumab-Qyyp
|
Roche | — | open 4.8 yrs to entry |
2031-03-11 | 0 | — |
| C | 15 |
EVENITY
ROMOSOZUMAB-AQQG
|
AMGEN INC | — | open 4.9 yrs to entry |
2031-04-09 | 0 | — |
| C | 15 | (unknown) | SAMSUNG BIOEPIS CO LTD | — | open 4.9 yrs to entry |
2031-04-25 | 0 | — |
| C | 15 |
Tivdak
tisotumab-vedotin
|
SEAGEN | $147M | distant 7 yrs to entry (early) |
2033-09-20 | 0 | — |
| C | 15 |
Spevigo
SPESOLIMAB
|
Boehringer Ingelheim Pharmaceuticals Inc | $300M | distant 8 yrs to entry (early) |
2034-09-01 | 0 | — |
| C | 15 |
Talvey
TALQUETAMAB
|
Janssen Biotech | $400M | distant 9 yrs to entry (early) |
2035-08-09 | 0 | — |
| C | 15 |
Elrexfio
elranatamab
|
Pfizer | $304M | distant 9 yrs to entry (early) |
2035-08-14 | 0 | — |
| C | 15 |
Vyloy
ZOLBETUXIMAB
|
Astellas | $100M | distant 10 yrs to entry (early) |
2036-10-18 | 0 | — |
| C | 15 |
Blenrep
BELANTAMAB MAFODOTIN
|
GSK | $300M | distant 11 yrs to entry (early) |
2037-10-23 | 0 | — |
| C | 10 | (unknown) | PARKE DAVIS | — | saturated Expired 50 yrs ago |
1976-04-01 | 0 | — |
| C | 10 | COLLAGENASE SANTYL | SMITH AND NEPHEW | — | saturated Expired 49 yrs ago |
1977-06-04 | 0 | — |
| C | 10 |
CHORIONIC GONADOTROPIN
Chorionic Gonadotropin
|
El Shatby University Hospital for Obstetrics and Gynecology | — | saturated Expired 41 yrs ago |
1985-03-05 | 0 | — |
| C | 10 | NOVAREL | FERRING | — | saturated Expired 40 yrs ago |
1986-01-15 | 0 | — |
| C | 10 | (unknown) | BEL MAR | — | saturated Expired 40 yrs ago |
1986-03-26 | 0 | — |
| C | 10 |
Pre-Pen
benzylpenicilloyl polylysine
|
Allerquest | — | saturated Expired 40 yrs ago |
1986-07-25 | 0 | — |
| C | 10 | (unknown) | FERRING | — | saturated Expired 39 yrs ago |
1986-12-13 | 0 | — |
| C | 10 | (unknown) | SERONO | — | saturated Expired 39 yrs ago |
1987-08-22 | 0 | — |
| C | 10 | MEGATOPE | ISO TEX | — | saturated Expired 38 yrs ago |
1988-02-23 | 0 | — |
| C | 10 | (unknown) | BRACCO | — | saturated Expired 38 yrs ago |
1988-02-23 | 0 | — |
| C | 10 | (unknown) | ISO TEX | — | saturated Expired 38 yrs ago |
1988-02-23 | 0 | — |
| C | 10 | (unknown) | ISO TEX | — | saturated Expired 38 yrs ago |
1988-02-23 | 0 | — |
Drug Landscape Pro
Export the full table to CSV
Free tier exports first 25 rows. Pro: unlimited CSV + JSON exports, programmatic API access on Team tier.
How the score works
Each biologic is scored 0-100 across four axes:
- Revenue at stake (40 pts) — Annual sales of the reference product. A $20B blockbuster carries a much bigger prize than a $200M niche biologic, even with identical exclusivity windows.
- BPCIA window state (30 pts) — Biologics whose 12-year reference exclusivity is expiring within 1-3 years score highest (perfect dev window). Already-expired and >5-year windows score lower.
- Patent fortress weakness (20 pts) — Average vulnerability score of the originator's active patents. Patents with vulnerability ≥70 are likely IPR-attackable.
- Indication breadth (10 pts) — Approximated from active patent count. More patents typically means more approved indications = larger commercial target.
Use cases
- Pipeline prioritisation — Biosimilar developers use this to rank targets when planning the next 3-5 years of development
- Investor due diligence — PE/VC investing in biosimilar manufacturers can sanity-check the company's announced target list
- Originator defence planning — Pharma companies can identify which of their own biologics carry the highest biosimilar risk
- Licensing screen — BD teams use it to identify biosimilar in-licensing opportunities ahead of competitor announcements
Methodology note: "Window open / imminent" includes biologics where 12-year BPCIA reference exclusivity has expired or expires within 12 months — biosimilar approval still requires patent clearance, so an expired window does not mean immediate launch.